Please login to the form below

Not currently logged in
Email:
Password:

Neuraceq

This page shows the latest Neuraceq news and features for those working in and with pharma, biotech and healthcare.

EMA unveils draft guidelines for Alzheimer’s disease research

EMA unveils draft guidelines for Alzheimer’s disease research

Although the last few years have seen a number of Alzeimer's diagnostics approved, among them GE Healthcare Vizamyl (flutemetamol) and Piramal's Neuraceq (florbetaben F18), research progress for a treatment

Latest news

  • CHMP backs Piramal's Alzheimer's imaging agent CHMP backs Piramal's Alzheimer's imaging agent

    Neuraceq recommended for approval in Europe. Piramal is close to winning EU approval for its Alzheimer's disease (AD) diagnostic Neuraceq after a positive opinion from the EMA's Committee for ... Piramal acquired rights to Neuraceq from Bayer in 2012,

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics